Tumor Necrosis Factor Inhibitors and the Risk of Anorectal Cancer in Patients with Inflammatory Bowel Disease: Is This a Consistent and Clinically Concerning Association?

Authors

DOI:

https://doi.org/10.22516/25007440.1303

Keywords:

Tumor necrosis factor inhibitors, inflammatory bowel diseases, rectal diseases, neoplasms, diagnosis, therapy

Abstract

Introduction: The association between the use of tumor necrosis factor inhibitors (anti-TNF agents) and malignancy in patients with inflammatory bowel disease (IBD) has been increasingly explored. The objective of this study was to review the current state of the art regarding this relationship from multiple perspectives, based on the evidence available to date.

Methodology: A comprehensive literature review was conducted using the metasearch engines PubMed, ScienceDirect, Embase, SciELO, Cochrane, and Medline, without restrictions on publication period. Bibliographic sources consistent with the stated objective were systematically selected.

Results: A clear and unified definition of this association remains elusive. Human papillomavirus (HPV) infection and long-standing perianal fistulizing disease represent the primary risk factors. The main pathophysiological mechanism involved is the induction of T-cell apoptosis. Clinical presentation may overlap with IBD activity. Diagnostic evaluation should be supported by advanced imaging techniques, high-resolution anoscopy (HRA), and histopathological studies. Regarding management, a careful risk–benefit assessment of continued anti-TNF therapy is required. Localized disease presentation is associated with recurrence and a low risk of complications.

Conclusions: Evidence exists supporting an association between TNF inhibitors and malignancy in patients with IBD, which may be extrapolated to a limited extent. The majority of available data supports a protective role. However, when squamous cell carcinoma of the anal canal and anal margin is evaluated independently, recommendations favor considering these patients as a high-risk group, warranting inclusion in structured surveillance programs.

Downloads

Download data is not yet available.

Author Biographies

Juan Sebastián Frías Ordoñez, Universidad Nacional de Colombia

Specialist Physician in Internal Medicine and Gastroenterology, Universidad Nacional de Colombia. Gastroenterologist, Hospital Internacional de Colombia, Bucaramanga. Research Group in Medical and Surgical Specialties, Fundación Cardiovascular de Colombia. Floridablanca, Colombia.

Luis Jorge Lombana Amaya, Clinica de Marly

Specialist Physician in Coloproctology. Coloproctologist, Clínica de Marly. Bogotá, Colombia.

Hernando Marulanda Fernandez, Centro de Gastroenterología y Endoscopia

Specialist Physician in Internal Medicine and Gastroenterology, Universidad Nacional de Colombia, Center for Gastroenterology and Endoscopy. Bogotá, Colombia.

William Otero-Regino, Universidad Nacional de Colombia

Specialist Physician in Internal Medicine and Gastroenterology. Gastroenterology and Digestive Endoscopy, Universidad Nacional de Colombia. Bogotá, Colombia.

References

Ananthakrishnan AN, Kaplan GG, Ng SC. Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century. Clin Gastroenterol Hepatol. 2020;18(6):1252-60. https://doi.org/10.1016/j.cgh.2020.01.028

Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol. 2021;14:17562848211059954. https://doi.org/10.1177/17562848211059954

Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G. Novel therapeutic options for people with ulcerative colitis: An update on recent developments with janus kinase (JAK) inhibitors. Clin Exp Gastroenterol. 2020;13:131-9. https://doi.org/10.2147/CEG.S208020

Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohn’s Colitis. 2016;10(8):989-97. https://doi.org/10.1093/ecco-jcc/jjw053

Ruder B, Atreya R, Becker C. Tumour necrosis factor alpha in intestinal homeostasis and gut related diseases. Int J Mol Sci. 2019;20(8):1887. https://doi.org/10.3390/ijms20081887

Alkhayyat M, Abureesh M, Gill A, Khoudari G, Abou Saleh M, Mansoor E, et al. Lower Rates of Colorectal Cancer in Patients with Inflammatory Bowel Disease Using Anti-TNF Therapy. Inflamm Bowel Dis. 2021;27(7):1052-60. https://doi.org/10.1093/ibd/izaa252

Muller M, D’Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: A systematic review. J Crohn’s Colitis. 2021;15(5):840-59. https://doi.org/10.1093/ecco-jcc/jjaa186

Williams CJM, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: Malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(5):447-58. https://doi.org/10.1111/apt.12624

Andersen NN, Pasternak B, Basit S, Andersson M, Svanström H, Caspersen S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. Jama. 2014;311(23):2406-13. https://doi.org/10.1001/jama.2014.5613

Targownik LE, Bernstein CN. Infectious and malignant complications of tnf inhibitor therapy in ibd. Am J Gastroenterol. 2013;108(12):1835-42. https://doi.org/10.1038/ajg.2013.294

Charkaoui M, Hajage D, Tubach F, Beaugerie L, Kirchgesner J. Impact of Anti-tumour Necrosis Factor Agents on the Risk of Colorectal Cancer in Patients with Ulcerative Colitis: Nationwide French Cohort Study. J Crohn’s Colitis. 2022;16(6):893-9. https://doi.org/10.1093/ecco-jcc/jjab184

Townsend CM, Khanna R, Wilson AS. A More Severe Non-melanoma Skin Cancer Phenotype Is Seen in Patients with Inflammatory Bowel Disease on Tumor Necrosis Factor-α Antagonists. Dig Dis Sci. 2021;66(12):4436-40. https://doi.org/10.1007/s10620-020-06773-7

Axelrad JE, Hashash JG, Itzkowitz SH. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary. Clin Gastroenterol Hepatol. 2024;22(7):1365-72. https://doi.org/10.1016/j.cgh.2024.03.032

Laredo V, García-Mateo S, Martínez-Domínguez SJ, López de la Cruz J, Gargallo-Puyuelo CJ, Gomollón F. Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management. Cancers (Basel). 2023;15(3):871. https://doi.org/10.3390/cancers15030871

Matsuno H, Mizushima T, Nezu R, Nakajima K, Takahashi H, Haraguchi N, et al. Detection of Anorectal Cancer among Patients with Crohn’s Disease Undergoing Surveillance with Various Biopsy Methods. Digestion. 2016;94(1):24-9. https://doi.org/10.1159/000446799

Greuter T, Vavricka S, König AO, Beaugerie L, Scharl M. Malignancies in Inflammatory Bowel Disease. Digestion. 2020;101(Suppl1):136-45. https://doi.org/10.1159/000509544

Tassone D, Basnayake C, Wright E, Lust M, Kamm MA, Niewiadomski O, et al. Risk factors for malignancy and serious infection in patients with inflammatory bowel disease: a retrospective analysis. Intern Med J. 2024;54(3):446-54. https://doi.org/10.1111/imj.16141

Souza RF, Caetano MAF, Magalhães HIR, Castelucci P. Study of tumor necrosis factor receptor in the inflammatory bowel disease. World J Gastroenterol. 2023;29(18):2733-46. https://doi.org/10.3748/wjg.v29.i18.2733

Craven B, Zaric V, Martin A, Mureau C, Egan LJ. Effect of genetic deletion or pharmacological antagonism of tumor necrosis factor alpha on colitis-associated carcinogenesis in mice. Inflamm Bowel Dis. 2015;21(3):485-95. https://doi.org/10.1097/MIB.0000000000000303

Atreya R, Zimmer M, Bartsch B, Waldner MJ, Atreya I, Neumann H, et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages. Gastroenterology. 2011;141(6):2026-38. https://doi.org/10.1053/j.gastro.2011.08.032

Ogawa H, Haneda S, Shibata C, Miura K, Nagao M, Ohnuma S, et al. Adenocarcinoma associated with perianal fistulas in crohn’s disease. Anticancer Res. 2013;33(2):685-90.

Miao X, Mao R, You Y, Zhou H, Qiu C, Li X, et al. Intracolic ultrasound molecular imaging: a novel method for assessing colonic tumor necrosis factor-α expression in inflammatory bowel disease. Mol Med. 2021;27(1):11-2. https://doi.org/10.1186/s10020-021-00379-z

Neurath MF. Molecular Endoscopy and in vivo Imaging in Inflammatory Bowel Diseases. Dig Dis. 2015;33(Suppl 1):32-6. https://doi.org/10.1159/000437062

Murthy SK, Bernstein CN, Nguyen GC, Jairath V, Riddell R, Fergusson D, et al. Interim Analysis of a Trial Evaluating the Utility of Non-Targeted Biopsies for Colorectal Neoplasia Detection in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024;22(7):1535-1538.e2. https://doi.org/10.1016/j.cgh.2023.12.007

Savio MC, Baldin RKS, Nóbrega NL, Nicollelli GM, Brenner AS, Rocha PB Da, et al. Prevalence of Anal Intraepithelial Lesions in Patients with Inflammatory Bowel Disease. J Coloproctology. 2021;41(3):222-7. https://doi.org/10.1055/s-0041-1730425

Clifford GM, Georges D, Shiels MS, Engels EA, Albuquerque A, Poynten IM, et al. A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer. 2021;148(1):38-47. https://doi.org/10.1002/ijc.33185

Albuquerque A. Cytology in Anal Cancer Screening: Practical Review for Clinicians. Acta Cytol. 2020;64(4):281-7. https://doi.org/10.1159/000502881

Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The lower anogenital squamous terminology standardization project for hpv-associated lesions: Background and consensus recommendations from the college of american pathologists and the american society for colposcopy and cervical pathology. J Low Genit Tract Dis. 2012;16(3):205-42. https://doi.org/10.1097/LGT.0b013e31825c31dd

Slesser AAP, Bhangu A, Bower M, Goldin R, Tekkis PP. A systematic review of anal squamous cell carcinoma in inflammatory bowel disease. Surg Oncol. 2013;22(4):230-7. https://doi.org/10.1016/j.suronc.2013.08.002

Velásquez JRM, González Awique PS, Miranda Ruíz CA, Muñoz Zuluaga M, Miranda Ruíz LF. Using High-Resolution Anoscopy to Detect Anal Dysplasia Due to Papillomavirus in Patients with Inflammatory Bowel Disease. Rev Colomb Gastroenterol. 2023;38(4):419-29. https://doi.org/10.22516/25007440.1048

Stier EA, Clarke MA, Deshmukh AA, Wentzensen N, Liu Y, Poynten IM, et al. International Anal Neoplasia Society’s consensus guidelines for anal cancer screening. Int J Cancer. 2024;154(10):1694-702. https://doi.org/10.1002/ijc.34850

Hillman RJ, Cuming T, Darragh T, Nathan M, Berry-Lawthorn M, Goldstone S, et al. 2016 IANS International Guidelines for Practice Standards in the Detection of Anal Cancer Precursors. J Low Genit Tract Dis. 2016;20(4):283-91. https://doi.org/10.1097/LGT.0000000000000256

Palefsky JM, Lee JY, Jay N, Goldstone SE, Darragh TM, Dunlevy HA, et al. Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. N Engl J Med. 2022;386(24):2273-82. https://doi.org/10.1056/NEJMoa2201048

Boaz E, Freund MR, Harbi A, Dagan A, Gilshtein H, Reissman P, et al. Anorectal Malignancies Presenting as a Perianal Abscess or Fistula. Am Surg. 2023;89(6):2572-6. https://doi.org/10.1177/00031348221101481

Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105(3):501-23. https://doi.org/10.1038/ajg.2009.727

Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2014;14(1):75-101. https://doi.org/10.1517/14712598.2014.858695

Holmer AK, Luo J, Russ KB, Park S, Yang JY, Ertem F, et al. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study. Clin Gastroenterol Hepatol. 2023;21(6):1598-1606.e5. https://doi.org/10.1016/j.cgh.2023.01.002

Thomson ABR, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn’s disease. World J Gastroenterol. 2012;18(35):4823-54. https://doi.org/10.3748/wjg.v18.i35.4823

Tandon P, Rhee GG, Schwartz D, McCurdy JD. Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn’s Disease: A Systematic Review. Dig Dis Sci. 2019;64(11):3066-77. https://doi.org/10.1007/s10620-019-05635-1

Wang LF, Chen PR, He SK, Duan SH, Zhang Y. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review. World J Gastroenterol. 2023;29(29):4481-98. https://doi.org/10.3748/wjg.v29.i29.4481

Waljee AK, Higgins PDR, Jensen CB, Villumsen M, Cohen-Mekelburg SA, Wallace BI, et al. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol. 2020;5(3):276-84. https://doi.org/10.1016/S2468-1253(19)30362-0

Lee KE, Sizemore JA, Kim G, Shen B, Sands BE. Impact of Biologics and Small-Molecule Agents on Postoperative Complications in IBD: A Systematic Review. Dis Colon Rectum. 2024;67(S1):S11-25. https://doi.org/10.1097/DCR.0000000000003222

Hammoudi N, Lehmann-Che J, Lambert J, Amoyel M, Maggiori L, Salfati D, et al. Prognosis and molecular characteristics of IBD-associated colorectal cancer: Experience from a French tertiary-care center. Dig Liver Dis. 2023;55(9):1280-7. https://doi.org/10.1016/j.dld.2023.02.011

Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, et al. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Clin Gastroenterol Hepatol. 2016;14(1):58-64. https://doi.org/10.1016/j.cgh.2015.07.037

Micic D, Komaki Y, Alavanja A, Rubin DT, Sakuraba A. Risk of Cancer Recurrence among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019;53(1):E1-11. https://doi.org/10.1097/MCG.0000000000000865

Figura 1. Consideraciones en el abordaje diagnóstico del cáncer anorrectal en relación con el uso de inhibidores del factor de necrosis tumoral en pacientes con enfermedad inflamatoria intestinal. Imagen elaborada con figuras de Servier Medical Art bajo sus propias condiciones de uso, con base en: Muller M, et al. J Crohn’s Colitis. 2021;15(5):840-59(7); Williams CJM, et al. Aliment Pharmacol Ther. 2014;39(5):447-58(8); Andersen NN, et al. JAMA. 2014;311(23):2406-13(9); Targownik LE, et al. Am J Gastroenterol. 2013;108(12):1835-42(10); Townsend CM, et al. Dig Dis Sci. 2021;66(12):4436-40(12); Axelrad JE, et al. Clin Gastroenterol Hepatol. 2024;22(7):1365-72(13); Laredo V, et al. Cancers (Basel). 2023;15(3):871(14); Matsuno H, et al. Digestion. 2016;94(1):24-9(15).

Published

2026-03-13

How to Cite

Frías Ordoñez, J. S., Lombana Amaya, L. J., Marulanda Fernandez, H., & Otero-Regino, W. (2026). Tumor Necrosis Factor Inhibitors and the Risk of Anorectal Cancer in Patients with Inflammatory Bowel Disease: Is This a Consistent and Clinically Concerning Association?. Revista Colombiana De Gastroenterología, 41(1), 51–61. https://doi.org/10.22516/25007440.1303

Issue

Section

Review articles

Altmetric

Escanea para compartir
QR Code
Crossref Cited-by logo
Article metrics
Abstract views767
Galley views397
PDF Views397
HTML views0
Other views0

Some similar items: